Taro Pharma, Sun Pharma’s U.S. Unit, Sees Revenue Improve But Outlook Remains Cautious

Taro Pharma contributes nearly half of parent Sun Pharma’s total US formulation sales.

Niraj Shah

Published On

29 Oct 2020, 02:49 PM IST

Last Updated On

29 Oct 2020, 02:49 PM IST

Sun Pharma headquarters in Mumbai. (Photographer: Kanishka Sonthalia/Bloomberg)

Sun Pharmaceutical Industries Ltd.’s U.S. subsidiary witnessed a rise in revenue over the preceding quarter, a period when the Covid-19 pandemic hurt sales of its key dermatology segment and as it adjusted for settlements of drug price-fixing charges.

Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.

WRITTEN BY

Niraj is the Executive Editor at NDTV Profit with over 18 years of experien... more

GET REGULAR UPDATES

RECOMMENDED FOR YOU

CFO Leaders: The Making Of Five Star CFOs

timelogo

Stocks Rise, Treasuries Fall on Stimulus Bets: Markets Wrap

timelogo

Stocks End Record-Setting Week With Further Gains: Markets Wrap

timelogo

The Mutual Fund Show: The Dos And Don’ts Of Online Investing

timelogo

POPULAR